Overview of Demyelinating Disorders

ByMichael C. Levin, MD, College of Medicine, University of Saskatchewan
Reviewed/Revised May 2023
View Patient Education

    Myelin sheaths cover many nerve fibers in the central and peripheral nervous system; they accelerate axonal transmission of neural impulses. Disorders that affect myelin interrupt nerve transmission; symptoms may reflect deficits in any part of the nervous system.

    Myelin formed by oligodendroglia in the central nervous system (CNS) differs chemically and immunologically from that formed by Schwann cells peripherally. Thus, some myelin disorders (eg, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, some other peripheral nerve polyneuropathies) tend to affect primarily the peripheral nerves, and others affect primarily the CNS (see table Disorders That Can Cause Demyelination of the Central Nervous System). The most commonly affected areas in the CNS are the brain, spinal cord, and optic nerves.

    Demyelination tends to be segmental or patchy, affecting multiple areas simultaneously or sequentially. Remyelination often occurs, with repair, regeneration, and complete recovery of neural function. However, extensive myelin loss is usually followed by axonal degeneration and often cell body degeneration; both may be irreversible.

    Demyelination should be considered in any patient with unexplained neurologic deficits. Primary demyelinating disorders are suggested by the following:

    • Diffuse or multifocal deficits

    • Sudden or subacute onset, particularly in young adults

    • Onset within weeks of an infection or vaccination

    • Deficits that wax and wane

    • Symptoms suggesting a specific demyelinating disorder (eg, unexplained optic neuritis or internuclear ophthalmoplegia suggesting multiple sclerosis)

    Specific tests and treatment depend on the specific disorder.

    Table
    Table

    References

    1. 1. Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al: Association between tumor necrosis factor inhibitor exposure and inflammatory Central Nervous System Events. JAMA Neurol 77 (8):937–946, 2020. doi: 10.1001/jamaneurol.2020.1162

    2. 2. Oliveira MCB, de Brito MH, Simabukuro, MM: Central nervous system demyelination associated with immune checkpoint inhibitors: Review of the literature. Front Neurol 11:538695, 2020. doi: 10.3389/fneur.2020.538695 eCollection 2020.

    Drugs Mentioned In This Article

    quizzes_lightbulb_red
    Test your KnowledgeTake a Quiz!
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID